News und Analysen

Intellia Therapeutics (NASDAQ:NTLA), a biotechnology company developing CRISPR-based gene-editing therapies, reported second quarter 2025 results on August 7, 2025. The headline news was a

Dentsply Sirona (NASDAQ:XRAY), a major player in dental products and technologies, released its second quarter results on August 7, 2025. The company reported GAAP revenue of $936 million and

Avadel Pharmaceuticals Plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to improve lives, released its earnings for Q2 2025 on August 7, 2025. The headline news is

Akebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company specializing in kidney disease treatments, reported its earnings on August 7, 2025, covering results for the quarter. The headline news

Insulet (NASDAQ:PODD), a medical device company specializing in wearable insulin delivery systems, released its second quarter 2025 earnings on August 7, 2025. The headline news was strong

Immunic (NASDAQ:IMUX), a late-stage biotechnology company focused on autoimmune and inflammatory diseases, released its second quarter 2025 results on August 7, 2025. The quarter was marked by

Ecovyst (NYSE:ECVT), a specialty catalyst and chemicals provider focused on industrial and environmental markets, released its second-quarter 2025 results on August 7, 2025. The main headlines: the

Incoming patent cliffs regarding some of Pfizer's (NYSE: PFE) largest revenue streams have been pressuring the pharmaceutical stock. The price is down, but its dividend payout keeps rising. Last

Veracyte (NASDAQ:VCYT), a leader in advanced cancer diagnostics, reported results for Q2 2025 on August 6, 2025. The headline news: the company outperformed expectations on both revenue and

CareDx (NASDAQ:CDNA), a molecular diagnostics company specializing in transplant care solutions, released its results for the second quarter of fiscal 2025 on August 6, 2025. The big news from the

Innoviva (NASDAQ:INVA), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share

Orion (NYSE:OEC), a leading global producer of carbon black, reported its second quarter results on August 6, 2025. The most notable news was that GAAP revenue came in at $466.4 million for Q2 2025

Pulmatrix (NASDAQ:PULM), a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that

Seres Therapeutics (NASDAQ:MCRB), a clinical-stage biotech focused on microbiome therapeutics, released its second quarter 2025 earnings on August 6, 2025. The main highlight was a narrowing net

AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earnings on August 6

Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its

BeOne Medicines (NASDAQ:ONC), a global oncology-focused pharmaceutical company, released results for Q2 2025 on August 6, 2025. The most notable news was a sustained acceleration across revenue

UnitedHealth Group (NYSE: UNH) has been in the news over the past several months, but not positively. Unfortunately, the CEO of its healthcare unit, Brian Thompson, was shot and killed late last

Novavax (NASDAQ:NVAX), known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP

Amentum (NYSE:AMTM), a leading provider of engineering, technical, and mission support services to government and commercial customers, reported results for Q3 FY2025 on August 5, 2025. The earnings

Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company’s GAAP

Cumberland Pharmaceuticals (NASDAQ:CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology, released its financial results for the second quarter on

Orion Energy Systems (NASDAQ:OESX), a provider of energy-efficient LED lighting and electric vehicle (EV) charging solutions, released its results for the quarter ended June 30, 2025, on August 6